drugset / Trial / NCT00741234
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in cohorts of patients with advanced hematologic malignancies. Arm C will assess the safety and tolerability of SB939 in combination with standard azacitidine therapy.
Timeline
- Start
- 2007-04
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pracinostat | Other / unclassified | — | Oral |
| Background | Azacitidine | Other / unclassified | — | Oral |